BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV...
BioCentury | Oct 21, 2013
Company News

Canterbury Laboratories, Hygeia Therapeutics, Histogen, Stratus Media Group deal

Stratus announced that it will merge with Hygeia and its spinout, Canterbury. The resulting company will remain publicly traded and be called Restorgenex Corp., which plans to build an anti-aging skincare brand for women over...
BioCentury | Sep 16, 2013
Company News

Intellect Neurosciences, Pluristem Therapeutics other news

Onetime biotech financier David Blech will report to prison on Sept. 30 after pleading guilty in May to two counts of securities fraud. Blech was fined $1.3 million and sentenced to 48 months of imprisonment....
BioCentury | Sep 5, 2005
Strategy

Novartis Loads Up: A long engagement

...industry was in the doldrums and suffering the repercussions of the failure of market maker D. Blech...
BioCentury | Mar 30, 1998
Company News

D. Blech & Co. finance news

...D. Blech & Co. to accounts at other brokerage firms, all to create the appearance that D. Blech...
...reducing its outstanding margin credit" (see BioCentury, April 28, 1997). Days after the scheme collapsed, D. Blech...
...released on bond pending sentencing Sept. 15, faces a maximum of 20 years in prison. D. Blech...
BioCentury | Mar 30, 1998
Finance

GeneMedicine Inc. (GMED)

GeneMedicine Inc. (GMED) The weekly change in the indexed market value of GeneMedicine Inc. (GMED, dotted line with triangles) compared to The Carson Life Sciences Index of 190 smaller cap companies (<$500M, solid line with...
BioCentury | Jan 26, 1998
Finance

Vivus bowls over NBC

Ebb & Flow NBC's refusal to air Vivus' commercial for its MUSE erectile dysfunction product during the Super Bowl may be a blessing in disguise. The company is ramping up a print and TV advertising...
BioCentury | Jul 28, 1997
Finance

GeneMedicine Inc. (GMED)

GeneMedicine Inc. (GMED) The weekly change in the indexed market value of GeneMedicine Inc. (GMED; dotted line with triangles) compared to The Carson Life Sciences Index of 190 smaller cap companies (<$500M, solid line with...
BioCentury | Jul 7, 1997
Company News

D. Blech & Co. finance news

...Andrea Likwornik argued that Blech is competent to plead guilty in the case involving his D. Blech...
...see BioCentury June 2). A hearing to review the competency report has not been scheduled. D. Blech...
BioCentury | Jun 2, 1997
Company News

D. Blech & Co. finance news

...Blech to enter a plea in a criminal securities fraud case regarding activities of his D. Blech...
...condition prior to accepting a guilty plea. A hearing has been scheduled for July 2. D. Blech...
Items per page:
1 - 10 of 44
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV...
BioCentury | Oct 21, 2013
Company News

Canterbury Laboratories, Hygeia Therapeutics, Histogen, Stratus Media Group deal

Stratus announced that it will merge with Hygeia and its spinout, Canterbury. The resulting company will remain publicly traded and be called Restorgenex Corp., which plans to build an anti-aging skincare brand for women over...
BioCentury | Sep 16, 2013
Company News

Intellect Neurosciences, Pluristem Therapeutics other news

Onetime biotech financier David Blech will report to prison on Sept. 30 after pleading guilty in May to two counts of securities fraud. Blech was fined $1.3 million and sentenced to 48 months of imprisonment....
BioCentury | Sep 5, 2005
Strategy

Novartis Loads Up: A long engagement

...industry was in the doldrums and suffering the repercussions of the failure of market maker D. Blech...
BioCentury | Mar 30, 1998
Company News

D. Blech & Co. finance news

...D. Blech & Co. to accounts at other brokerage firms, all to create the appearance that D. Blech...
...reducing its outstanding margin credit" (see BioCentury, April 28, 1997). Days after the scheme collapsed, D. Blech...
...released on bond pending sentencing Sept. 15, faces a maximum of 20 years in prison. D. Blech...
BioCentury | Mar 30, 1998
Finance

GeneMedicine Inc. (GMED)

GeneMedicine Inc. (GMED) The weekly change in the indexed market value of GeneMedicine Inc. (GMED, dotted line with triangles) compared to The Carson Life Sciences Index of 190 smaller cap companies (<$500M, solid line with...
BioCentury | Jan 26, 1998
Finance

Vivus bowls over NBC

Ebb & Flow NBC's refusal to air Vivus' commercial for its MUSE erectile dysfunction product during the Super Bowl may be a blessing in disguise. The company is ramping up a print and TV advertising...
BioCentury | Jul 28, 1997
Finance

GeneMedicine Inc. (GMED)

GeneMedicine Inc. (GMED) The weekly change in the indexed market value of GeneMedicine Inc. (GMED; dotted line with triangles) compared to The Carson Life Sciences Index of 190 smaller cap companies (<$500M, solid line with...
BioCentury | Jul 7, 1997
Company News

D. Blech & Co. finance news

...Andrea Likwornik argued that Blech is competent to plead guilty in the case involving his D. Blech...
...see BioCentury June 2). A hearing to review the competency report has not been scheduled. D. Blech...
BioCentury | Jun 2, 1997
Company News

D. Blech & Co. finance news

...Blech to enter a plea in a criminal securities fraud case regarding activities of his D. Blech...
...condition prior to accepting a guilty plea. A hearing has been scheduled for July 2. D. Blech...
Items per page:
1 - 10 of 44